## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.8% below STRENGTH zone (4.0-10.0%); PEG 2.58 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($78.28)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. GEHC Expands Healthcare Access Through Indonesia MoH Partnership Deal**
- Source: The Globe and Mail | 20251217T181104 | Bullish | Relevance: 100%
- GE HealthCare (GEHC) has partnered with Indonesia’s Ministry of Health under the SIHREN program to expand access to advanced diagnostic and care technologies, particularly in underserved regions. This collaboration supports Indonesia's healthcare modernization and positions GEHC for long-term growth in emerging markets, including supplying over 300 CT scanners. The initiative aligns with GEHC's international expansion strategy and reinforces its role as a key partner for public health systems.

**2. GEHC Expands Healthcare Access Through Indonesia MoH Partnership Deal**
- Source: The Globe and Mail | 20251217T180749 | Bullish | Relevance: 100%
- GE HealthCare (GEHC) has partnered with Indonesia's Ministry of Health under the SIHREN program to enhance healthcare access nationwide by deploying advanced diagnostic technologies, training, and digital health solutions. This collaboration will see GEHC supply over 300 CT scanners across Indonesia's 38 provinces, supporting the country's largest-ever healthcare infrastructure investment and expanding GEHC's presence in emerging markets. The agreement aims to improve patient outcomes through earlier diagnosis and treatment for conditions like cancer, stroke, and heart disease.

**3. Vaso Corp Extends Sales Agreement With GE Healthcare Through 2030**
- Source: TradingView — Track All Markets | 20251217T150750 | Bullish | Relevance: 100%
- Vaso Corp has announced an extension of its sales agreement with GE Healthcare through the year 2030. This development was reported by Refinitiv and involves GE Healthcare Technologies Inc.

**4. GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners**
- Source: PharmiWeb.com | 20251217T050751 | Bullish | Relevance: 100%
- GE HealthCare will supply over 300 advanced CT scanners to public hospitals across all 38 provinces in Indonesia by 2028 as part of the country's Strengthening Indonesia’s Health Referral Network (SIHREN) program. This collaboration aims to enhance diagnostic access and improve early diagnosis and treatment of non-communicable diseases, cancer, stroke, and heart disease for over 280 million Indonesians. The initiative also underscores GE HealthCare's commitment to local manufacturing, capability building, and knowledge transfer to strengthen Indonesia’s healthcare ecosystem.

**5. Northside Capital Management LLC Has $10.55 Million Stock Position in GE HealthCare Technologies Inc. $GEHC**
- Source: MarketBeat | 20251217T131626 | Bullish | Relevance: 100%
- Northside Capital Management LLC significantly increased its stake in GE HealthCare Technologies Inc. during the third quarter, now holding 140,507 shares valued at approximately $10.55 million. Other institutional investors also made substantial investments, bringing total institutional ownership to 82.06%. GE HealthCare reported strong Q3 earnings, exceeding analyst expectations, and announced a new quarterly dividend.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $88 | $83 | +6% |
| 2025-12-11 | Jefferies | $105 | $95 | +11% |
| 2025-11-21 | BTIG | $87 | $87 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Neutral |
| 2025-12-11 | Jefferies | main | Buy |
| 2025-11-21 | BTIG | reit | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.6% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.58 signals overvaluation risk, limited margin of safety. Forward P/E 16.8x stretched relative to 8% growth. Quality metrics strong (ROE 24%). Analyst sentiment positive (2 raises, avg +8%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $37.7B |
| Beta | 1.24 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.58 |
| Forward P/E | 16.8 |
| Current P/E | 18.1 |
| YoY Growth | 8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.4% to 1.8% (-3.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.2pp (needs >4.0% for momentum thesis). MRS_5 (-0.7%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.80% (CS: 57) | Neutral |
| RSI_14 | 56.1 | Neutral |
| MACD Histogram | -0.20 | Bearish |
| vs SMA20 | 1.011x | Above |
| vs SMA50 | 1.067x | Above |
| vs SMA200 | 1.108x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $82.52
- **Stop Loss:** $78.28 (5.1% risk)
- **Target:** $86.76 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 224
- **Position Value:** $18,484.48
- **Portfolio %:** 18.48%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*